Substitution and reduction of platinum(IV) complexes by a nucleotide, guanosine 5′-monophosphate

被引:45
作者
Choi, S [1 ]
Mahalingaiah, S [1 ]
Delaney, S [1 ]
Neale, NR [1 ]
Masood, S [1 ]
机构
[1] Middlebury Coll, Dept Chem & Biochem, Middlebury, VT 05753 USA
关键词
D O I
10.1021/ic9809815
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
A series of Pt-IV anticancer complexes with different reduction potentials has been investigated for their reactivity toward 5'-guanosine monophosphate (5'-GMP). The Pt-IV complexes studied were Pt-IV(trans-d,l)(1,2-(NH2)(2)C6H10)Cl-4 (tetraplatin, Pt-IV(dach)Cl-4; dach = diaminocyclohexane), cis,trans,cis-[Pt-IV((CH3)(2)CHNH2)(2)(OH)(2)Cl-2] (iproplatin, Pt-IV(ipa)(2)(OH)(2)Cl-2; ipa = isopropylamine), cis, trans,cis-[Pt-IV(en)(OH)(2)Cl-2] (Pt-IV(en)(OH)(2)Cl-2; en = ethylenediamine), Pt-IV(en)Cl-4, and cis,trans,cis-[Pt-IV(en)(OCOCH3)(2)Cl-2] (Pt-IV(en)(OCOCH3)(2)Cl-2. The reactivity was monitored by the decreased H-1 NMR peak intensity at 8.2 ppm due to H8 of free 5'-GMP and the increased intensity of a new peak around 8.6 ppm due to H8 of 5'-GMP bound to Pt-II. The reactivity followed the order of cathodic reduction potentials of the Pt-IV complexes: Pt-IV(dach)Cl-4 (-90 mV) >> Pt-IV(en)Cl-4 (-160 mV) > Pt-IV(en)(OCOCH3)(2)Cl-2 (-546 mV) > Pt-IV(ipa)(2)(OH)(2)Cl-2 (-730 mV). The most reactive complex, Pt-IV(dach)Cl-4, showed an additional weak peak at 9.2 ppm due to H8 of the 5'-CMP bound to the Pt-IV complex, indicating the existence of a Pt-IV intermediate. H-1 NMR, UV/visible absorption spectra, and high-performance liquid chromatograms suggest that the final product is Pt-IV(dach)(5'-GMP)(ox5'-GMP), where ox5'-GMP is oxidized 5'-GMP. A plausible mechanism is that there is an initial substitution of one Pt-IV/ligand by a 5'-GMP molecule, followed by a two-electron reduction, and finally a second substitution by another 5'-GMP. In the presence of excess 5'-GMP (at least 20-fold), ox5'-GMP seems to be replaced by 5'-GMP to form Pt-II(dach)(5'-GMP)(2). UV/visible absorption spectroscopy shows that the formation of the Pt-IV intermediate by substitution is a very slow process followed by reduction. The reduction is characterized by a relatively fast exponential decay. The addition of a small amount of cis-[Pt-II(NH3)(2)Cl-2] shortened the slow formation time of the intermediate, implicating the occurrence of a Pt-II-assisted substitution reaction. These reactions may lead to a better understanding of the anticancer activity of Pt-IV complexes.
引用
收藏
页码:1800 / 1805
页数:6
相关论文
共 25 条
[11]   BULKY LIGAND SUBSTITUENT EFFECT ON THE REACTION OF 5'-GMP WITH PT(1,3-DIAMINE) - ROTATION OF 5'-GMP ABOUT THE PT-N BOND AND KINETIC EFFECTS [J].
INAGAKI, K ;
DIJT, FJ ;
LEMPERS, ELM ;
REEDIJK, J .
INORGANIC CHEMISTRY, 1988, 27 (02) :382-387
[12]  
KELLAND LR, 1992, CANCER RES, V52, P822
[13]   PREPARATION, CHARACTERIZATION, AND ANTITUMOR-ACTIVITY OF NEW ETHYLENEDIAMINE PLATINUM(IV) COMPLEXES CONTAINING MIXED CARBOXYLATE LIGANDS [J].
KHOKHAR, AR ;
DENG, YJ ;
KIDO, Y ;
SIDDIK, ZH .
JOURNAL OF INORGANIC BIOCHEMISTRY, 1993, 50 (02) :79-87
[14]   GLUTATHIONE-MEDIATED MODULATION OF TETRAPLATIN ACTIVITY AGAINST SENSITIVE AND RESISTANT TUMOR-CELLS [J].
KIDO, YC ;
KHOKHAR, AR ;
SIDDIK, ZH .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (09) :1635-1642
[15]   REACTION-PRODUCTS OF [PT(ETHYLENEDIAMINE)(DIMETHYL SULFOXIDE)CL]CL AND [PT(ETHYLENEDIAMINE)CL2] WITH D(GPG) AND 5'GMP - UNAMBIGUOUS EVIDENCE FOR STABLE 1-1 INTERMEDIATE N7 ADDUCTS WITH COORDINATED DIMETHYL-SULFOXIDE [J].
LEMPERS, ELM ;
BLOEMINK, MJ ;
REEDIJK, J .
INORGANIC CHEMISTRY, 1991, 30 (02) :201-206
[16]  
MASON WR, 1972, COORDIN CHEM REV, V7, P241
[17]   IN-VITRO PLATINUM DRUG CHEMOSENSITIVITY OF HUMAN CERVICAL SQUAMOUS-CELL CARCINOMA CELL-LINES WITH INTRINSIC AND ACQUIRED-RESISTANCE TO CISPLATIN [J].
MELLISH, KJ ;
KELLAND, LR ;
HARRAP, KR .
BRITISH JOURNAL OF CANCER, 1993, 68 (02) :240-250
[18]   DNA INTERACTIONS OF ANTITUMOR PLATINUM(IV) COMPLEXES [J].
NOVAKOVA, O ;
VRANA, O ;
KISELEVA, VI ;
BRABEC, V .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 228 (03) :616-624
[19]   Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates [J].
Poon, GK ;
Mistry, P ;
Raynaud, FI ;
Harrap, KR ;
Murrer, BA ;
Barnard, CFJ .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1995, 13 (12) :1493-1498
[20]  
RAHMAN A, 1988, CANCER RES, V48, P1745